Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Shrestha, P. Whitaker, R. Mozdiak, R. Ahmed, M. Arif, T. Capstick, J. Watson (Leeds, United Kingdom). Incidence and timing of hepatotoxicity due to anti-tuberculous treatment. Eur Respir J 2011; 38: Suppl. 55, 4408

Member's Comments

No comment yet.

Related content which might interest you: Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis Source: ISSN=ISSN 1810-6838, ISBN=, page=69 Year: 2007 Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008 Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Source: Eur Respir J 2007; 29: 347-351 Year: 2007 Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis Source: Eur Respir J 2014; 43: 602-609 Year: 2013 Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002 Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016 High incidence of new onset joint pain in patients receiving fluoroquinolones as part of anti-tuberculous treatment Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009 Paradoxical response to adequate antituberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 724s Year: 2004 Frequency of side effects in antibiotic treatment for pneumonia Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019 Standardized second-line anti-TB treatment of multidrug-resistant tuberculosis during pregnancy; maternal and neonatal safety and outcome Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 Characteristics of patients who interrupted anti-tuberculosis treatment Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 Risk factors for anti-tuberculosis treatment failure Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011 Manifestations of hypersensitivity to anti-tuberculosis drugs Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019 Severe adverse effects of antitubercular drugs and patient management Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Antituberculosis chemotherapy toxicity reduction Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012